
Tenaya Therapeutic (TNYA) Stock Forecast & Price Target
Tenaya Therapeutic (TNYA) Analyst Ratings
Bulls say
Tenaya Therapeutics Inc. is showing promising advancements in its product candidates, with increased projected chances of success for TN-201 and TN-401, boosting confidence in their potential to secure accelerated approvals. The company has demonstrated consistent improvements in left ventricular metrics and positive trends in cardiac biomarkers, suggesting effective treatment outcomes in their preclinical cohorts. Encouraging safety profiles and meaningful clinical improvements observed in patients further solidify the foundation for a potentially successful trajectory in addressing heart disease.
Bears say
Tenaya Therapeutics is facing significant risks due to potential delays in transitioning its preclinical assets to clinical trials, which could negatively affect market sentiment and lead to downward revisions in financial estimates. Additionally, the emergence of important safety signals during clinical trials, particularly related to immune reactions, poses a further threat to the company's prospects. Compounding these challenges, insufficient manufacturing capacity could materially constrain future forecasts and hinder the company's ability to deliver its product candidates to market.
This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.
Tenaya Therapeutic (TNYA) Analyst Forecast & Price Prediction
Start investing in Tenaya Therapeutic (TNYA)
Order type
Buy in
Order amount
Est. shares
0 shares